BOULDER, Colo.--(BUSINESS WIRE)--Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: ...

BURLINGTON, Vt. (WCAX) - The University of Vermont has been touting the impressive credentials of its new freshman class, and one school within UVM is particularly proud of its new students who hope ...

ENV-294 is a clinical-stage small molecule designed to address the shared pathways underlying multiple inflammatory conditions via a first-in-class mechanism. ENV-294 entered Phase 1 studies in ...